Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.OGX-427, systemic treatment of solid tumors including prostate, non-small cell lung, breast, ovarian, and bladder cancers
Subscribe to our email newsletter
OncoGenex has reported the first patient dosing in an open label, dose-escalation, phase 1 clinical trial, evaluating OGX-427 when administered directly into the bladder in patients with bladder cancer.
The trial is separate from an ongoing phase 1 trial of OGX-427 administered systemically in patients with various solid tumors.
OGX-427 is a second-generation antisense drug that is designed to reduce production of Heat Shock Protein 27 (Hsp27), a cell-survival protein that inhibits apoptotic cell death through multiple pathways.
The study, which will enroll up to 36 patients with bladder cancer, is designed to determine the safety and potential benefit of OGX-427 administered directly into the bladder using a catheter, which is called intravesical instillation.
In addition, the study will measure the direct effect of OGX-427 on expression of Hsp27 in bladder tumor cells. It will also determine the pharmacokinetics and pharmacodynamics of OGX-427, when delivered by intravesical instillation.
Scott Cormack, president and CEO of OncoGenex, said: This phase 1 trial of OGX-427 is an attractive trial design as removal of bladder tumor samples after treatment allows us to demonstrate inhibition of Hsp27 expression at the cellular level in the tumor.
By conducting this trial through an investigator-sponsored trial with leading clinical researchers at the Vancouver Prostate Centre allows us to advance the development of OGX-427 without a significant commitment of our financial resources, he added.